Abstract Library

#1462 Cross-Talk Between EGFR and IGF1R Influences the Response to RTK Inhibitors in Bronchopulmonary (BP)-NET Cell Lines

Introduction: BP-NETs represent ~30% of all neuroendocrine tumors. BP-NET treatment is challenging due to onset of resistance to chemo and targeted therapies. EGFR and IGF1R had been associated with tumor onset and progression in several neoplasia.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Gagliano T

Authors: Gagliano T, Gentilin E, Benfini K, Falletta S, Di Pasquale C,

Keywords: BP-NET RTK,

#1039 Receptor Tyrosine-Kinases Inhibition: New Insights on Therapeutic Implications of EGFR and IGF1R in Human Bronchopulmonary NET

Introduction: The main treatment for bronchopulmonary NET(BP-NET) is surgery, which is not feasible for infiltrating and metastatic disease, where medical therapy is tried. Identifying new therapeutic targets is important to provide adequate medical treatment for patients with BP-NET. Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor (TKI), is mainly described to inhibit VEGF

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Gagliano T

Authors: Gagliano T, Benfini K, Gentilin E, Falletta S, Di Pasquale C,

Keywords: RTK, BP-NET, IGF1R, EGFR,

#933 The Cytotoxic Effect of Sunitinib on Human Bronchial Carcinoid Cell Lines and Primary Cultures is Counteracted by EGF and IGF-1, but not by VEGF

Introduction: Bronchial carcinoids (BC) are rare tumors originating from endocrine cells dispersed in the respiratory epithelium. The main BC treatment is surgery, but which is not feasible for large, infiltrating and metastatic disease. In these settings, medical therapy is often tried. Therefore it is important to identify new therapeutic targets and new molecules capable of providing adequate medical treatment for patients with BC. Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Gagliano T, Gennari G, Tassinari M, Bellio M, Molè D,

Keywords: BC, RTK, Sunitinib,

#680 Role of EGF Pathway in Regulating Bronchial Carcinoid Cell Proliferation

Introduction: Bronchial carcinoids (BC) are rare neuroendocrine tumors. Surgery is not feasible for infiltrating and metastatic disease. Medical therapy is often tried but is represented by chemotherapy and radiation, while somatostatin analogues are employed for symptomatic control. It is necessary to identify new molecules capable of providing medical treatment in cases for which surgical removal is not feasible. EGF, TGFα are growth factors which were demonstrated to be important in neuroendocrine tumors. EGF and TGFα bind to the EGF receptor and lead to the transcription of genes that regulate cell proliferation.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Gagliano T, Bellio M, Molè D, Gentilin E, Minoia M,

Keywords: EGF, EGFR, BC,